JP Morgan Raises TEVA Price Target to $50

JP Morgan has reaffirmed its Overweight rating on Teva Pharmaceutical Industries Limited (NYSE: TEVA) on October 12, 2026. The firm raised its price target to $50 from $40. This indicates a positive outlook for the company as it continues to navigate the pharmaceutical market.

Other Institutional Activity in Teva

Blackrock Inc. trimmed its position in Teva, selling 1,244,144 shares, leaving it with 63,894,301 shares valued at about $2.65 billion. Harel Insurance Investments & Financial Services Ltd. increased its stake by 2,182,905 shares, bringing its total to 48,138,805 shares worth approximately $2.00 billion. Phoenix Financial Ltd. added 154,006 shares, totaling 42,933,367 shares valued at about $1.78 billion. WCM Investment Management, LLC grew its holdings by 493,938 shares, ending with 41,315,232 shares worth about $1.71 billion. Clal Insurance Enterprises Holdings Ltd. raised its stake by 2,149,204 shares, totaling 40,596,506 shares valued at around $1.68 billion.

Teva Pharmaceutical Industries Limited Stock Up 1.2%

Teva's shares are currently trading at $41.22 as of October 16, 2026. This price is above its 50-day moving average by about 8.1% and above its 200-day moving average by 20.9%. However, the stock is about 1.9% below its 52-week high of $42.02. This positioning suggests that the stock has room for growth, especially as it trades below the analyst's target price.

Recent Earnings

Teva reported trailing twelve-month revenue of $17.32 billion and earnings per share (EPS) of $0.59. The company's revenue growth year-over-year stands at -0.8%, while its net margin is 4.1%. Teva is set to announce its next earnings on November 3, 2026.

Insider Buying and Selling at Teva Pharmaceutical Industries Limited

Several insiders have sold shares recently. On August 3, 2026, Officer Eric A. Hughes sold 25,578 shares for a total of $892,051 at an average price of $34.88. On August 21, 2026, Officer Amir Weiss sold 9,445 shares valued at $355,301. Officer Brian Savage sold 7,342 shares on September 18, 2026, for $285,215. Additionally, Director Roberto A. Mignone sold 367,600 shares for $14.36 million on the same date at an average price of $39.06.

Analysts Set New Price Targets

On October 12, 2026, JP Morgan maintained its Overweight rating on Teva with a new price target of $50. Earlier, on September 4, UBS maintained a Buy rating with a target of $48, and on September 9, Leerink Partners initiated coverage with an Outperform rating and a target of $45. Oppenheimer also initiated coverage on September 23 with a target of $50, while TD Cowen initiated a Buy rating with a target of $55 on October 1. The consensus recommendation for Teva is a Strong Buy, with a mean price target of $47.58 from 12 analysts.

About Teva Pharmaceutical

Teva Pharmaceutical Industries Limited develops and distributes generic and specialty medicines and biopharmaceutical products globally. With a significant presence in the healthcare sector, Teva's recent analyst ratings reflect positive market sentiment as it prepares for upcoming earnings and continues to adapt to industry changes.

Bottom Line

Teva is gearing up for its earnings report on November 3, 2026. With JP Morgan's recent reiteration of its Overweight rating and a price target increase, investors will be watching closely for how the stock performs in the coming weeks.